Results 1 to 10 of about 29,583 (162)

Diagnostic Value of cfDNA in Pancreatic Cancer

Zhongliu Fangzhi Yanjiu, 2022
Objective To explore the diagnostic value of cfDNA in pancreatic cancer. Methods A total of 467 patients with pancreatic cancer and 129 healthy controls were enrolled. cfDNA concentration was detected using the QuantiDNA Direct cfDNA Test (DiaCarta) kit.
XU Yijun, ZHU Mingchen
doaj   +1 more source

Adoption of a non-invasive prenatal test (NIPT) in prenatal screening in Moscow: first results

Russian Open Medical Journal, 2021
The objective — To assess the effectiveness of including NIPT in the structure of prenatal diagnostics in Moscow. Material and Methods — Totally 5,181 pregnancies undergoing screening for fetal trisomy using NIPT during the period from 01.04.2020 to 30 ...
Anton S. Olenev, Elena E. Baranova, Olesya V. Sagaydak, Alexandra M. Galaktionova, Ekaterina S. Kuznetsova, Madina T. Kaplanova, Maxim S. Belenikin, Ekaterina N. Songolova   +7 more
doaj   +1 more source

Circulating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index [PDF]

, 2017
Circulating cell-free DNA (cfDNA) has been considered an interesting diagnostic/prognostic plasma biomarker in tumor-bearing subjects. In cancer patients, cfDNA can hypothetically derive from tumor necrosis/apoptosis, lysed circulating cells, and some ...
A Asmarinah, A Fawzy, A Jemal, A Matos, Alessandro Sammarco, Andrea Saccani, Antonio Mollo, BG Wang, BT Kurien, C Alix-Panabières, C Qian, CH Lee, Chiara Bedin, Chiara Romualdi, D Bostock, D El-Gayar, D Madhavan, D Merlo, Davide Trez, DMW Schaefer, Donato Nitti, E Coustan-Smith, E Gormally, EM Tan, F Salvianti, FH Igney, GB Gelaleti, Giorgia Beffagna, H Schwarzenbach, H Schwarzenbach, J Beck, J Ferlay, JC Thompson, K Jung, K Pilichou, K Sorenmo, K Sorenmo, Kristy L. Richards, KS Borge, L Ouyang, L Pena, L Pena, Laura Cavicchioli, LE Lowes, M Agostini, M Geng, M Goldschmidt, M Shackleton, M Stroun, M Stroun, Marco Agostini, Marta Mainenti, MB Giacona, Michelangelo Campanella, MV Jain, N Sleeckx, N Umetani, N Umetani, P Anker, P Hofman, P Rivera, R Agassi, R Brodey, R Kumaraguruparan, R Kumaraguruparan, Raffaella De Maria, Re Ellsworth, S Baspinar, S Cargnin, S Iqbal, S Jahr, S Volik, SA Leon, Silvia Ferro, T Hao, T Imamura, T Skvortsova, Valentina Zappulli, W Ayala, W Wang   +79 more
core   +14 more sources

Cell-free DNA methylome profiling by MBD-seq with ultra-low input

Epigenetics, 2022
Methylation signatures in cell-free DNA (cfDNA) have shown great sensitivity and specificity in the characterization of tumour status and classification of tumour types, as well as the response to therapy and recurrence. Currently, most cfDNA methylation
Jinyong Huang, Alex C. Soupir, Liang Wang   +2 more
doaj   +1 more source

Benefits of Plasma Over Other Body Fluids for Circulating Tumor DNA Detection in Genitourinary Tumors

Société Internationale d’Urologie Journal, 2023
None.
Manishkumar S. Patel, Liang Wang
doaj   +1 more source

Dynamics of methylated cell-free DNA in the urine of non-small cell lung cancer patients

Epigenetics, 2022
High levels of methylated DNA in urine represent an emerging biomarker for non-small cell lung cancer (NSCLC) detection and are the subject of ongoing research.
Sander Bach, Birgit M.M. Wever, Mark A. van de Wiel, Joris D. Veltman, Sayed M.S. Hashemi, Geert Kazemier, Idris Bahce, Renske D.M. Steenbergen   +7 more
doaj   +1 more source

cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome

Endocrine Oncology, 2023
We report a case of metastatic pancreatic neuroendocrine carcinoma associated with paraneoplastic Cushing’s syndrome, successively treated with five lines of treatment (platin-etoposide, LV5FU2-dacarbazine, FOLFIRINOX, pembrolizumab, and paclitaxel) and ...
Laura Gerard, David Barthelemy, Arnaud Gauthier, Valerie Hervieu, Jonathan Lopez, Benjamin Gibert, Helene Lasolle, Laurence Chardon, Jessica Garcia, Gérald Raverot, Léa Payen, Thomas Walter   +11 more
doaj   +1 more source

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. [PDF]

, 2014
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can respond to BRAF inhibitors.
Cabrilo, Goran, Erlander, Mark G, Hassaine, Latifa, Holley, Veronica R, Janku, Filip, Kosco, Karena, Kurzrock, Razelle, Leppin, Lorieta, Lin, Patrick P, Meric-Bernstam, Funda, Poole, Jason C, Stepanek, Vanda M, Vibat, Cecile Rose T   +12 more
core   +8 more sources

Immunoaging – the effect of age on serum levels of NET biomarkers in men: a pilot study

International Journal of Occupational Medicine and Environmental Health, 2023
Objectives The study aimed to evaluate the impact of aging on the formation of neutrophil extracellular traps (NETs). The impaired formation of NETs is the cause of an abnormal innate immune response.
Marzena Garley, Wioleta Justyna Omeljaniuk, Radosław Motkowski, Wioletta Ratajczak-Wrona, Ewa Jabłońska, Daniel Filipkowski, Angelika Edyta Charkiewicz   +6 more
doaj   +1 more source

Ultrashort ssDNA in Retinoblastoma Patients Blood Plasma Detected by a Novel High Resolution HPCL Technique: a Preliminary Report

Acta Medica, 2020
A significant population of ultrashort (50–150n) single-stranded DNA fragments were found in exosome-free blood plasma of retinoblastoma patients (6.84 ng mL−1), but not in plasma of healthy donors.
Kirill V. Ermakov, Alexander A. Bukhvostov, Alexander S. Vedenkin, Sergey V. Stovbun, Anton S. Dvornikov, Dmitry A. Kuznetsov   +5 more
doaj   +1 more source